Table 1.
Tyrosine kinase inhibitors currently used to treat GIST
| Line of therapy | Trial demonstrating efficacy | N | Median time to progression (months) | Partial response | Stable disease | |
|---|---|---|---|---|---|---|
| Imatinib | First | Demetri et al, 200222 | 147 | 24 | 54% | 28% |
| Sunitinib | Second | Demetri et al, 200646 | 207 | 6.1 (27.3 weeks) | 7% | 58% |
| Regorafenib | Third or later | Demetri et al, 201348 | 133 | 4.8 | 5% | 71% |
| Pazopanib | Third or later | Mir et al, 201650 | 40 | 3.4 | 0% | 84% |
| Sorafenib | Third or later | Park et al, 201253 | 31 | 4.9 | 13% | 52% |
| Dasatinib | First Second or later |
Montemurro et al, 201851 Schuetze et al, 201852 |
42 50 |
13.6 2.9 |
74%a 25% |
14% NR |
| Nilotinib | Third or later | Reichardt et al, 201249 | 165 | 4 (119 days) | <1% | 53% |
Note: aResponse measured by FDG-PET avidity.
Abbreviations: N, number of patients; NR, not reported; GIST, gastrointestinal stromal tumor.